Literature DB >> 21336145

Quality of life of primary open angle glaucoma patients in lagos, Nigeria: clinical and sociodemographic correlates.

Adeola Olukorede Onakoya1, Chigozie A Mbadugha, Olufisayo T Aribaba, Olayinka O Ibidapo.   

Abstract

PURPOSE: To evaluate the quality of life (QOL) of primary open angle glaucoma (POAG) patients attending a tertiary eye institution in Lagos, Nigeria and identify clinical and sociodemographic factors affecting it.
METHODS: A hospital-based cross-sectional analytical study design was used to compare 132 patients with varying degrees of severity of glaucoma (cases) with age-matched and sex-matched controls with essentially normal eyes and no family history of glaucoma.
RESULTS: POAG patients had reduced QOL as defined by the 2 instruments used: the National Eye Institute Visual Function Questionnaire25 (NEIVFQ25) and the 15-item Glaucoma Quality of life Questionnaire (GQL-15). The mean QOL score obtained with the NEIVFQ25 for the cases was 85.2 (±16.07) and 96.7 (±2.34) for the controls. Using the GQL-15 scale, the mean QOL score for the cases was 24.07 (±12.4), whereas for the controls the score was 15.75 (±1.85). Early or mild glaucoma was associated with reduced QOL compared with the controls. Glaucoma patients had the greatest difficulty with glare and dark adaptation subscale of the GQL-15. Increasing severity of disease defined by increasing visual field deficit (mean deviation values) correlated significantly with worsening QOL [Spearman ρ (r) values ranging from 0.32 to 0.43]. Contrast sensitivity correlated moderately with QOL (r ranges from 0.43 to 0.47; P=0.001). Cup-to-disc ratios, visual acuity, and visual field indices (mean deviation) correlated with QOL scores of both tools with r values ranging from 0.28 to 0.49 for the GQL-15 and 0.38 to 0.54 for the NEIVFQ25. Age had a negative impact on QOL (r=-0.30 for the NEIVFQ25 and 0.30 for the GQL-15) and affected all the subscales of the GQL-15 and most subscales of the NEIVFQ25 except ocular pain (P=0.40), mental health (P=0.13), color vision (P=0.05), and role difficulty (P=0.11). Women generally had better vision-related QOL scores (P=0.001 for the NEIVFQ25 and 0.005 for the GQL-15). Higher educational status was associated with better QOL scores (P<0.05). Ethnicity, religion, marital status, and living situation had no significant effect on QOL scores.
CONCLUSIONS: POAG reduces QOL even in the early stages of the disease, as there was a significant reduction in the QOL of patients with mild glaucoma compared with the controls. It showed a clear trend of worsening QOL scores with increasing severity of disease. The correlation observed between QOL scores and objective measures of visual function suggest that inclusion of QOL assessment in clinical practice could be highly informative and should be explored further.

Entities:  

Mesh:

Year:  2012        PMID: 21336145     DOI: 10.1097/IJG.0b013e31820d7cfd

Source DB:  PubMed          Journal:  J Glaucoma        ISSN: 1057-0829            Impact factor:   2.503


  21 in total

1.  Cost Analysis of Commonly used Combination of Drugs in Primary Open Angle Glaucoma.

Authors:  Shivaprasad Kalakappa Kumbar; Mrutyunjay Mirje; Gurudatta Moharir; Ambadasu Bharatha
Journal:  J Clin Diagn Res       Date:  2015-05-01

2.  Risk Factors Associated with Progression to Blindness from Primary Open-Angle Glaucoma in an African-American Population.

Authors:  Alexander Pleet; Melanie Sulewski; Rebecca J Salowe; Raymond Fertig; Julia Salinas; Allison Rhodes; William Merritt Iii; Vikas Natesh; Jiayan Huang; Harini V Gudiseva; David W Collins; Venkata Ramana Murthy Chavali; Paul Tapino; Amanda Lehman; Meredith Regina-Gigiliotti; Eydie Miller-Ellis; Prithvi Sankar; Gui-Shuang Ying; Joan M O'Brien
Journal:  Ophthalmic Epidemiol       Date:  2016-06-27       Impact factor: 1.648

3.  Quality of life of glaucoma patients in China: sociodemographic, clinical, and psychological correlates-a cross-sectional study.

Authors:  Chuandi Zhou; Shaohong Qian; Peixia Wu; Chen Qiu
Journal:  Qual Life Res       Date:  2013-09-24       Impact factor: 4.147

4.  Validation of the Glaucoma Quality of Life-15 Questionnaire in Serbian language.

Authors:  Ivan Sencanic; Tatjana Gazibara; Jelena Dotlic; Miroslav Stamenkovic; Vesna Jaksic; Marija Bozic; Anita Grgurevic
Journal:  Int J Ophthalmol       Date:  2018-10-18       Impact factor: 1.779

5.  Cross-Sectional Study on the Coping Strategies Among Glaucoma Patients Attending a Secondary Eye Clinic in Calabar, Nigeria.

Authors:  Egbula Nkanu Eni; Bassey Eyo Edet; Affiong Andem Ibanga; Roseline Ekanem Duke
Journal:  Clin Ophthalmol       Date:  2020-05-13

6.  Is glaucoma comprehension associated with psychological disturbance and vision-related quality of life for patients with glaucoma? A cross-sectional study.

Authors:  Xiang Mei Kong; Wen Qing Zhu; Jia Xu Hong; Xing Huai Sun
Journal:  BMJ Open       Date:  2014-05-26       Impact factor: 2.692

7.  Epidemiological properties of primary open angle glaucoma in Nigeria.

Authors:  Lawan Abdu
Journal:  J Ophthalmol       Date:  2013-05-26       Impact factor: 1.909

8.  Linguistic and psychometric validation of the Chinese version of the Glaucoma Quality of Life-15 (GQL-15-CHI): a cross-sectional study.

Authors:  Chuandi Zhou; Jing Yao; Shaohong Qian; Peixia Wu
Journal:  Health Qual Life Outcomes       Date:  2013-11-05       Impact factor: 3.186

9.  Patient-Reported Vision-Related Quality-of-Life Differences between Primary Angle-Closure Glaucoma and Primary Open-Angle Glaucoma.

Authors:  Hui-Chen Cheng; Chao-Yu Guo; Yu-Jing Chen; Mei-Ju Chen; Yu-Chieh Ko; Nicole Huang; Catherine Jui-Ling Liu
Journal:  PLoS One       Date:  2016-09-30       Impact factor: 3.240

10.  Primary Open-Angle Glaucoma in Individuals of African Descent: A Review of Risk Factors.

Authors:  Rebecca Salowe; Julia Salinas; Neil H Farbman; Aishat Mohammed; Joshua Z Warren; Allison Rhodes; Alexander Brucker; Meredith Regina; Eydie Miller-Ellis; Prithvi S Sankar; Amanda Lehman; Joan M O'Brien
Journal:  J Clin Exp Ophthalmol       Date:  2015-07-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.